Artiva Biotherapeutics (ARTV) Cash & Equivalents (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Cash & Equivalents data on file, last reported at $21.0 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $21.0 million, down 31.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.0 million (down 31.07% YoY), and the FY2025 annual result was $26.7 million, down 33.64% from the prior year.
• Cash & Equivalents eased to $21.0 million in Q1 2026 per ARTV's latest filing, from $26.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $65.9 million in Q3 2023 and troughed at $21.0 million in Q1 2026.
• A 4-year average of $40.3 million and a median of $37.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents declined 15.18% in 2024, then tumbled 54.35% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $53.5 million in 2023, then decreased by 24.8% to $40.2 million in 2024, then slumped by 33.64% to $26.7 million in 2025, then retreated by 21.52% to $21.0 million in 2026.
• Business Quant data shows ARTV's Cash & Equivalents at $21.0 million in Q1 2026, $26.7 million in Q4 2025, and $25.5 million in Q3 2025.